Answers are grounded in this paper and cite their sources.
Herein, we report a case of thromboembolic disease occurring during endemic Kaposi’s disease treated with bleomycin. Kaposi’s disease is a vascular and fibroblastic disorder caused by human herpes virus type 8. The endemic form remains prevalent yet with a less severe prognosis. The first line of systemic treatment in our country is classically a monotherapy with bleomycin. This case of endemic Kaposi’s disease was treated with bleomycin monotherapy that reportedly caused thromboembolic disease on two occasions after administration. This was one of the rarely reported effects of bleomycin in monochemotherapy, especially in the case of the treatment of endemic Kaposi’s disease, considering the chronology of the appearance of this effect in your patient.
No takes yet. Share an insight, caveat, or question.
Moussa et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: